

# Hervé© Watier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3419901/publications.pdf>

Version: 2024-02-01

46  
papers

4,436  
citations

257357

24  
h-index

182361

51  
g-index

59  
all docs

59  
docs citations

59  
times ranked

4541  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pourquoi tant d'anticorps monoclonaux en thérapie et comment appréhender cette profusion ? Revue Francophone Des Laboratoires, 2021, 2021, 40-47.	0.0	0
2	Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients. International Journal of Molecular Sciences, 2021, 22, 6051.	1.8	2
3	4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis. Frontiers in Immunology, 2020, 11, 573040.	2.2	6
4	Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open, 2020, 6, e001047.	1.8	36
5	History, extensive characterization and challenge of anti-tetanus serum from World War I: exciting remnants and deceived hopes. Immunologic Research, 2020, 68, 7-12.	1.3	2
6	Evolutionary Story of the Low/Medium-Affinity IgG Fc Receptor Gene Cluster. Frontiers in Immunology, 2019, 10, 1297.	2.2	14
7	Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development. MAbs, 2019, 11, 1341-1350.	2.6	32
8	New structural formats of therapeutic antibodies for rheumatology. Joint Bone Spine, 2018, 85, 47-52.	0.8	6
9	Rituximab mechanisms of action in B-CLL: a new piece of the puzzle. Oncotarget, 2018, 9, 32732-32733.	0.8	0
10	MABTope: A Method for Improved Epitope Mapping. Journal of Immunology, 2018, 201, 3096-3105.	0.4	26
11	Theranostic of biopharmaceuticals. , 2017, 175, 67-74.		5
12	Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges. MAbs, 2017, 9, 735-741.	2.6	19
13	Contribution of physiologists to the identification of the humoral component of immunity in the 19th century. MAbs, 2017, 9, 774-780.	2.6	9
14	MABDelivery: Administration routes for antibody therapy Third LabEx MABImprove industrial workshop, July 2, 2015 Tours, France. MAbs, 2017, 9, 579-585.	2.6	6
15	Obinutuzumab: what is there to learn from clinical trials?. Blood, 2017, 130, 581-589.	0.6	70
16	Rethinking the INN system for therapeutic antibodies. MAbs, 2017, 9, 5-11.	2.6	12
17	Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice. Journal of Immunology, 2017, 199, 418-424.	0.4	16
18	Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action. Molecular Immunology, 2016, 77, 126-131.	1.0	21

#	ARTICLE	IF	CITATIONS
19	IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. <i>Journal of Immunology</i> , 2016, 196, 607-613.	0.4	55
20	Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 814-816.	1.5	19
21	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. <i>MAbs</i> , 2015, 7, 1205-1211.	2.6	67
22	Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 286-297.	1.1	66
23	MABImprove. <i>MAbs</i> , 2014, 6, 803-804.	2.6	5
24	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 118-128.	1.1	68
25	Antibody biosimilars: Fears or opportunities?. <i>MAbs</i> , 2014, 6, 805-809.	2.6	8
26	Unexplained Abuses of Human IgG Subclass Denomination in Antibody Patents. <i>BioDrugs</i> , 2014, 28, 327-329.	2.2	0
27	Towards an individualised target concentration of adalimumab in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1428-1429.	0.5	25
28	Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. <i>MAbs</i> , 2013, 5, 614-619.	2.6	55
29	Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E-Mediated Anaphylaxis. <i>Journal of Clinical Oncology</i> , 2012, 30, 334-334.	0.8	34
30	Should anti-TNF drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?. <i>Joint Bone Spine</i> , 2012, 79, 109-112.	0.8	27
31	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011, 13, R105.	1.6	134
32	Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 411-416.	1.0	27
33	IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 383-387.	0.7	72
34	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009, 113, 3765-3772.	0.6	116
35	Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies. <i>Journal of Clinical Oncology</i> , 2008, 26, 5489-5491.	0.8	58
36	Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 523-529.	1.0	172

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics of rituximab and its clinical use: Thought for the best use?. Critical Reviews in Oncology/Hematology, 2007, 62, 43-52.	2.0	109
38	Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Critical Reviews in Oncology/Hematology, 2007, 62, 34-42.	2.0	79
39	Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality. Critical Reviews in Oncology/Hematology, 2007, 64, 226-233.	2.0	26
40	An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab. Therapeutic Drug Monitoring, 2006, 28, 169-174.	1.0	93
41	Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opinion on Biological Therapy, 2005, 5, S29-S36.	1.4	20
42	Rituximab-Dependent Cytotoxicity by Natural Killer Cells. Cancer Research, 2004, 64, 4664-4669.	0.4	395
43	The active role played by xenogeneic endothelial cells in the indirect presentation pathway is not lymphocyte trans-co-stimulation. Transplant International, 2004, 17, 787-794.	0.8	4
44	From the bench to the bedside: ways to improve rituximab efficacy. Blood, 2004, 104, 2635-2642.	0.6	494
45	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc $\gamma$ RIIIa gene. Blood, 2002, 99, 754-758.	0.6	1,819
46	EVIDENCE OF NONINVOLVEMENT OF SWINE MHC CLASS II IN THE IN VITRO PROLIFERATIVE RESPONSE OF HUMAN LYMPHOCYTES TO PORCINE ENDOTHELIAL CELLS. Transplantation, 1995, 59, 897-901.	0.5	21